Treatment of Cryptorchidism with Pernasal Gonadotropin-Releasing Hormone Therapy

• Published in: Fertility and sterility Vol. 29; no. 5; pp. 546 - 551
• Main Authors: Happ, Joachim, Kollmann, Fritz, Krawehl, Cordula, Neubauer, Manfred, Krause, Ulrich, Demisch, Karl, Sandow, Jürgen, von Rechenberg, Wolfrad, Beyer, Jürgen
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.1978
• Subjects: Administration, Intranasal; Child; Child, Preschool; Cryptorchidism - therapy; Follicle Stimulating Hormone - blood; Humans; Infant; Luteinizing Hormone - blood; Male; Pituitary Hormone-Releasing Hormones - therapeutic use; Prolactin - blood; Thyroid Hormones - blood
• ISSN: 0015-0282; 1556-5653
• DOI: 10.1016/S0015-0282(16)43283-8

Twenty-five boys between 1 and 10 years of age with unilateral or bilateral cryptorchidism were treated with 200pg of gonadotropin-releasing hormone (GnRH) pernasally six times daily until descensus was completed, or for 10 weeks at most. Complete descent of the testes occurred in 16 patients, usually after 2 to 5 weeks of treatment. No adverse side effects have been observed. Radioimmunologic measurements of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, and prolactin, carried out before treatment, at the end of treatment, and 6 months after treatment, showed a transitory increase of the LH responsiveness to GnRH in only four of the patients and in the group as a whole a slight but significant decrease of FSH responsiveness. There were no signs of precocious puberty. GnRH antibodies were not found.